Author of

• 12211

  +

  MO15 - Novel Genes and Pathways (ID 89)

  • Event: WCLC 2013
  • Type: Mini Oral Abstract Session
  • Track: Biology
  • Presentations: 1
  • Moderators:Y. Ohe, G. Reid
  • Coordinates: 10/29/2013, 16:15 - 17:45, Parkside Ballroom A, Level 1

  • 12216

    +

    MO15.05 - Oncogenic ARAF mutation in lung adenocarcinoma (ID 2860)

    16:35 - 16:40  |  Author(s): M. Imielinski
    • Abstract
    • Presentation
    • Slides

    Background
    Targeted cancer therapies often induce “outlier” responses in molecularly defined patient subsets.

    Methods
    One patient with advanced-stage lung adenocarcinoma, who was treated with oral sorafenib, demonstrated a complete clinical and radiographic remission for five years. Whole genome sequencing (WGS) and RNA sequencing (RNA-seq) on primary tumor and normal samples from this patient was performed.

    Results
    We identified a somatic mutation, ARAF S214C, present in the cancer genome and expressed at high levels. Additional mutations affecting this residue of ARAF and a nearby residue in the related kinase RAF1 were demonstrated across 1% of an independent cohort of lung adenocarcinoma cases. The ARAF mutants were shown to transform immortalized human airway epithelial cells and were associated with in vitro sorafenib sensitivity.

    Conclusion
    These results suggest that mutant ARAF may be a novel oncogenic driver in lung adenocarcinoma and an indicator of sorafenib response.

    Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.